Indivior (INDV) Q2 EPS Jumps 104%

Indivior (NASDAQ:INDV), a global pharmaceutical company known for its treatments for opioid use disorder (OUD), reported results on July 31, 2025. The main news was a sharp outperformance compared to analyst estimates, with non-GAAP EPS of $0.51 beating the $0.25 consensus. Revenue (GAAP) reached $302 million, above the $241.67 million forecast and 1.0% higher than the same quarter last year. Improvements in SUBLOCADE sales and steadier pricing for SUBOXONE Film helped offset rising U.S. marketing expenses. Management raised its full-year fiscal 2025 guidance for both net revenue and adjusted EBITDA, citing strong first-half results. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Indivior develops and markets medicines focused on the treatment of addiction and serious mental illness, with a particular emphasis on opioid use disorder (OUD). Its portfolio includes SUBLOCADE, a long-acting injectable, as well as SUBOXONE Film, sublingual tablets, and other products for OUD management and opioid overdose reversal.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool